Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
ERYTECH today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company’s US investor base.
ERYTECH today announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests.
ERYTECH reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia
ERYTECH Pharma prize winner of Deloitte Technology Fast 50 2014 Rhône-Alpes Bourgogne Auvergne
Finance – ERYTECH Pharma participates on February 9-10, 2015 to BIO CEO INVESTOR Conference taking place in New York City, NY, USA
ERYTECH is attending JP Morgan in San Francisco, Ca, USA from January 12 to 13, 2015
SCIENTIFIC CONGRESS – ERYTECH Pharma participates in ASH annual meeting 2014 from December 6 to 9 in San Francisco, CA, USA.
FINANCE – ERYTECH Pharma attends German Equity Forum from November 24 to 26, 2014 in Frankfurt, Germany.